Mirum Pharmaceuticals Inc. (MIRM) exhibits 41.0% gross margins and -3.9% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 24.0x enterprise multiple and 6.9% implied options volatility.
Sustained 41.0% gross profitability converts into -4.2% operating margin and -3.9% ROIC, outpacing sector cost of capital.
ROIC: -3.9% // GM: 41.0%YoY revenue trajectory of +54.7% paired with 0.98% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +54.7% // FCF YLD: 0.98%Altman Z-Score of 6.29 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 6.29 // F-SCORE: 8/9Trading at 24.0x trailing P/E (32.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±6.9% implied move with a 0.85 put/call ratio around $85.00 max pain.
IMPL MOVE: ±6.9% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend -4.5% net margins.
NET MARGIN: -4.5% // D/E: 0.70x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for MIRM & activate live FRED threshold breach alerts.